Download NuGEN Introduces Target Enrichment Technology for

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Nutriepigenomics wikipedia , lookup

Metagenomics wikipedia , lookup

Gene expression programming wikipedia , lookup

Gene expression profiling wikipedia , lookup

Gene therapy of the human retina wikipedia , lookup

NEDD9 wikipedia , lookup

Neuronal ceroid lipofuscinosis wikipedia , lookup

Saethre–Chotzen syndrome wikipedia , lookup

Vectors in gene therapy wikipedia , lookup

Oncogenomics wikipedia , lookup

RNA silencing wikipedia , lookup

Genomics wikipedia , lookup

Gene desert wikipedia , lookup

Gene nomenclature wikipedia , lookup

Helitron (biology) wikipedia , lookup

Gene therapy wikipedia , lookup

Microevolution wikipedia , lookup

Artificial gene synthesis wikipedia , lookup

Designer baby wikipedia , lookup

Site-specific recombinase technology wikipedia , lookup

Therapeutic gene modulation wikipedia , lookup

RNA-Seq wikipedia , lookup

Transcript
MEDIA RELEASE
For more information
Newsroom
Businesswire Australia and New Zealand
[email protected]
28-Aug-2014 9:20 AM
Topic: Health
NuGEN Introduces Target Enrichment Technology for
Comprehensive Detection of Gene Fusion Events in
Oncology Research and Clinical Testing
~Most Complete NGS Target Enrichment Solution for the Detection of Gene Fusion Events Enabled in a
Simple and Rapid Workflow~
SAN CARLOS, Calif.--(BUSINESS WIRE)--NuGEN Technologies, Inc., a market leader in the development of
solutions for Next Generation Sequencing (NGS) applications, has announced the release of a novel targeted
enrichment method that, in a single assay, will detect all possible fusion events involving 446 cancer fusion genes as
curated by the Wellcome Trust Sanger Institute's Catalog of Somatic Mutations in Cancer (COSMIC). The
proprietary NuGEN technology uses a unique single primer strategy that requires only one partner exon to be
targeted, thereby enabling not only detection of known fusion events but also discovery of novel gene fusions and
alternative splice forms.
“Screening samples for a broad range of gene fusions has been a costly and time consuming process until now”
NuGEN's proprietary Single Primer Enrichment Technology (SPET) is the core technology that delivers a highly
sensitive method for detection of low abundance gene fusion transcripts with as little as 10 ng of total RNA derived
from either fresh or formalin-fixed paraffin-embedded tissues. The easy, cost-effective assay employs a single day,
rapid workflow.
“Screening samples for a broad range of gene fusions has been a costly and time consuming process until now,”
commented Doug Amorese, VP of R&D at NuGEN. “The SPET technology for targeted RNA sequencing enables
NGS analysis to identify any fusion event in the targeted gene set and will be an important approach both in basic
research and the development of RNA-Seq based cancer diagnostic and prognostic tests.”
The Ovation Fusion Panel Target Enrichment System queries 5769 exons and is available with 8, 32 and 96
barcodes for efficient library generation and cost effective sequencing analysis.
In addition, customized gene fusion panels using the same technology can also be made to specific user
requirements. “We are actively working with partners who are currently using the standard Ovation Fusion Panel
Target Enrichment System in clinical research programs and anticipate moving forward with custom designed fusion
panels for use in clinical testing in the future,” said Joe Don Heath, NuGEN's Vice President of Diagnostic Market
Development. NuGEN offers custom design services for target enrichment products with a three week turnaround
from design to delivery and has an active diagnostic partner program for the supply of sample preparation
technology.
About NuGEN
NuGEN Technologies is a San Carlos, CA company focused on innovative solutions for RNA and DNA that enable
life scientists to do more with less. With reagent solutions that are quick, easy to use, and amenable to automation,
NuGEN empowers researchers and clinicians to prepare genomic samples of any size, from almost any source,
regardless of the intended application or technology platform. For more information please visit www.nugen.com.
Ovation and NuGEN are registered trademarks of NuGEN Technologies, Inc.
Contacts
NuGEN Technologies, Inc.
Carol Short, 650-590-3002
[email protected]
About Businesswire
Tens of thousands of communications and organisations around the world trust Business Wire to issue their press
releases, multimedia and regulatory filings to news media, digital platforms, regulatory authorities and industry
influencers. With thousands of distribution and targeting options that reach 162 countries in 50+ languages and 193
industry trade categories, Business Wire gives you access to the world's most powerful press release network. Built
on our patented simultaneous and secure NX network and augmented with partnerships with international and
national news agencies, Business Wire is a valued and trusted source for breaking news by reporters, investors and
consumers. Founded in 1961, Business Wire has 32 bureaus around the globe and is a fully owned subsidiary of
Berkshire Hathaway, a Fortune 5 company.
On Twitter: businesswire
On LinkedIn: http://www.linkedin.com/company/business-wire
More from Business Wire Australia and New Zealand
Get the latest media releases, subscribe to release alerts, and download print and web ready media files at:
http://newsboost.com/newsroom/businesswire